Duque-Afonso, J., Finke, J., Ngoya, M., Galimard, J., Schetelig, J., Eder, M., . . . Mohty, M. (2025). Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation, 60(3), 373. https://doi.org/10.1038/s41409-024-02499-6
Chicago-referens (17:e uppl.)Duque-Afonso, Jesús, et al. "Comparison of Fludarabine/melphalan (FM140) with Fludarabine/melphalan/BCNU (FBM110) in Patients with Relapsed/refractory AML Undergoing Allogeneic Hematopoietic Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party." Bone Marrow Transplantation: Official Journal of the European Society for Blood and Marrow Transplantation 60, no. 3 (2025): 373. https://doi.org/10.1038/s41409-024-02499-6.
MLA-referens (9:e uppl.)Duque-Afonso, Jesús, et al. "Comparison of Fludarabine/melphalan (FM140) with Fludarabine/melphalan/BCNU (FBM110) in Patients with Relapsed/refractory AML Undergoing Allogeneic Hematopoietic Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party." Bone Marrow Transplantation: Official Journal of the European Society for Blood and Marrow Transplantation, vol. 60, no. 3, 2025, p. 373, https://doi.org/10.1038/s41409-024-02499-6.
